Comprehensive TCGA biomarker discovery platform with over 100 genes across LUAD, LUSC, and SCLC subtypes. Machine learning, AI interpretation, PDF exports.
Lung cancer is the leading cause of cancer death worldwide
Annual Incidence
2.48M
new cases globally
Annual Deaths
1.82M
worldwide mortality
5-Year Survival
21.7%
global average
Cancer Death Rank
#1
leading cause
Bifurcation into NSCLC (85%) and SCLC (15%) with molecular subtypes
NSCLC • 85% of lung cancer
The most common type, accounting for 85% of lung cancers. Grows and spreads more slowly than SCLC.
LUAD (Adenocarcinoma)
40%Most common lung cancer; occurs in outer regions; more common in non-smokers, women, younger patients
Median survival: 52.4 mo • 5-yr: 25%
LUSC (Squamous Cell Carcinoma)
30%Strongly associated with smoking; occurs in central bronchi; more common in men
Median survival: 41.2 mo • 5-yr: 22%
Large Cell Carcinoma
5%Poorly differentiated; grows rapidly; can occur anywhere in lung
Median survival: 34.6 mo • 5-yr: 15%
Adenosquamous Carcinoma
4%Mixed features of adenocarcinoma and squamous
Median survival: 32.4 mo • 5-yr: 18%
SCLC • 15% of lung cancer
Aggressive, rapidly growing cancer strongly linked to smoking. Often metastatic at diagnosis.
SCLC-A
70%Classical neuroendocrine; ASCL1-high
Median: 12.4 mo
SCLC-N
11%NEUROD1-high; often with MYC amplification; worse prognosis
Median: 10.2 mo
SCLC-P
7%Tuft cell-like; POU2F3-high; non-neuroendocrine
Median: 11.8 mo
SCLC-Y / Inflamed
12%YAP1 or immune-inflamed; may benefit from immunotherapy
Median: 14.2 mo
Modifiable and non-modifiable causes of lung cancer
Browse all 115 biomarkers with filters, sort, and quick actions
1017 samples, LUAD vs LUSC, top mutations, molecular data
51 signaling pathways with associated biomarkers
Run 5 algorithms simultaneously or individually + custom CSV upload
25 curated lung cancer miRNAs with clinical context
Full LungVar-ML dissertation by Adhaar Kohli — 9-stage pipeline, AUC 0.913